Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.
Benzinga’s Top Ratings Upgrades, Downgrades For August 10, 2023
Upgrades For Roblox Corp (NYSE:RBLX), Wedbush upgraded the previous rating of Neutral to Outperform. Roblox earned $0.46 in…
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on Wednesday.
Earnings Scheduled For August 9, 2023
Companies Reporting Before The Bell
• Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Preview: Deciphera Pharmaceuticals’s Earnings
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Wednesday, 2023-05-03. Here’s what investors…
Stifel Is Bullish On This ‘Competitive Late-Comer’ In Gastric Cancer Space
Stifel has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a $24 price target. The company’s Predictive Resistance…
Reported Late Tuesday March 14, Deciphera Pharmaceuticals Announces QINLOCK Included In NCCN Guidelines For The Treatment Of Second-Line GIST Patients And FDA Grants Breakthrough Therapy Designation For QINLOCK In Second-Line GIST Patients With Mutatio…
– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib –
HC Wainwright & Co. Reiterates Buy on Deciphera Pharmaceuticals, Maintains $25 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and maintains $25 price target.